title: Potential cardiotoxicity with the use of DuP-941: a case report.
abstract: OBJECTIVE
  To describe the clinical and pathological features of a patient with probable cardiotoxicity related to a newer chemotherapeutic agent, DuP-941.
  
  
  METHODS
  A 42-year-old woman with metastatic breast carcinoma treated with only DuP-941 developed, and died of, heart failure for which no other explanation was apparent.
  
  
  RESULTS
  Clinically the patient's heart failure resembled that associated with anthracycline cardiotoxicity, as did the pathological features seen at autopsy.
  
  
  CONCLUSIONS
  DuP-941 is a new chemotherapeutic drug that may supplant some uses of the anthracyclines because the former may have less cardiotoxicity. This report suggests that in some cases DuP-941 may have cardiotoxic effects as well.
authors.affiliation: Department of Medicine, University of Ottawa Heart Institute, Ottawa Civic Hospital, Ontario.
authors.forename: S M
authors.initials: SM
authors.lastname: Walsh
authors.forename: V M
authors.initials: VM
authors.lastname: Walley
authors.forename: L
authors.initials: L
authors.lastname: Chandra
authors.forename: S D
authors.initials: SD
authors.lastname: Huan
authors.forename: J P
authors.initials: JP
authors.lastname: Veinot
authors.forename: L A
authors.initials: LA
authors.lastname: Higginson
mesh_terms: D000328:Adult; D000880:Anthraquinones / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology* / Q000601:surgery; D017809:Fatal Outcome; D005260:Female; D006321:Heart / Q000187:drug effects; D006333:Heart Failure / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008207:Lymphatic Metastasis; D008408:Mastectomy; D008854:Microscopy, Electron; D009206:Myocardium / Q000648:ultrastructure; D009210:Myofibrils / Q000648:ultrastructure; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D047069:Pyrazolones
chemical_list: D000880:Anthraquinones; D000970:Antineoplastic Agents; D011720:Pyrazoles; D047069:Pyrazolones; C050637:losoxantrone